Articles And Documents of Interest

Drug libraries help clinicians identify potential infusion errors before they harm patients by checking the pump's programming against a curated list of medications and fluids and their medically appropriate dose ranges. If programming exceeds drug library limits, smart pumps will alert clinicians. Baxter International, Inc., has created a comprehensive guide to building a smart infusion system drug library and integrating it with the electronic health record.

 Click here to obtain a free download of the entire guide.

Oncology Survey

Three organizations collaborated on a survey to determine if practitioners had implemented current recommended safe practices for IV vincristine administration, general oncology safe practices, and safe practices for oral chemotherapy. A survey was distributed to members of the Hematology Oncology Pharmacy Association (HOPA) and the International Society of Pharmacy Practitioners (ISOPP) using Survey Monkey TM. The Institute of Safe Medication Practices (ISMP) also solicited readers of its Medication Safety Alert! ® to respond to the survey. A comparison to results from a survey conducted by ISMP in 2006 on safe practices for IV vincristine was also conducted. 

Click here to obtain a free download of the entire article

American Society of Parenteral and Enteral Nutrition Practice (ASPEN)Enteral Practice Recommendations: Published in the Journal of Parenteral and Enteral Nutrition Volume 33 Number 2 March/April 2009 122-167

Click here for free download of the entire article.


The ISMP QuarterWatch report for May 2008 brought to FDA and the public’s attention data showing strong safety signals with varenicline (CHANTIX ) in the 4th Quarter 2007. Chantix accounted for more reported serious adverse events than any other prescription drug during this quarter.  Other QuarterWatch reports since then have also detailed serious side effects including aggressive behavior and other neuropsychiatric symptoms. This information contributed to an FDA alert sent on July 1, 2009:

Varenicline (marketed as Chantix) and Bupropion (marketed as Zyban, Wellbutrin, and generics)
Audience: Neuropsychiatric healthcare professionals, patients

FDA notified healthcare professionals and patients that it has required the manufacturers of the smoking cessation aids varenicline (Chantix) and bupropion (Zyban and generics) to add new Boxed Warnings and develop patient Medication Guides highlighting the risk of serious neuropsychiatric symptoms in patients using these products.These symptoms include changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. The added warnings are based on the continued review of postmarketing adverse event reports for varenicline and bupropion received by the FDA.  These reports included those with a temporal relationship between the use of varenicline or bupropion and suicidal events and the occurrence of suicidal ideation and suicidal behavior in patients with no history of psychiatric disease.
Healthcare professionals should advise patients to stop taking varenicline or bupropion and contact a healthcare provider immediately if they experience agitation, depressed mood, and any changes in behavior that are not typical of nicotine withdrawal, or if they experience suicidal thoughts or behavior.

Read the complete MedWatch 2009 Safety summary, including links to the FDA Public Health Advisory, Information for Healthcare Professionals and previous MedWatch alerts, at:



Home | Contact UsEmployment  |   Legal Notices | Privacy Policy | Help Support ISMP
 Med-ERRS | Medication Safety Officer Society Medication Safety Officers Society | Consumer Medication Safety For consumers
ISMP Canada | ISMP Spain  | ISMP Brasil  | International Group  | Pennsylvania Patient Safety Authority

200 Lakeside Drive, Suite 200, Horsham, PA 19044, Phone: (215) 947-7797,  Fax: (215) 914-1492
© 2018 Institute for Safe Medication Practices. All rights reserved